背景:迷幻医学的研究主要集中在平民人群上。需要进一步的研究来了解这些治疗方法对退伍军人人群是否有效。目标:这里,我们在墨西哥寻求认知和心理健康问题治疗的创伤暴露型特种作战部队退伍军人(SOFV)中,研究迷幻辅助治疗的有效性.方法:从伊博加因和5-甲氧基-N,有创伤暴露史的SOFV的N-二甲基色胺(5-MeO-DMT)临床治疗方案。该临床计划收集前瞻性临床计划评估数据,如背景特征,症状严重程度,功能(例如,对生活的满意度,创伤后应激障碍症状,抑郁症状,焦虑症状,睡眠障碍,心理灵活性,功能上的残疾,认知功能,神经行为症状,愤怒,自杀意念),通过四个时间点的在线调查(基线/治疗前,one-,三-,和治疗后六个月)。结果:大多数样本(n=86;平均年龄=42.88,SD=7.88)是白种人(87.2%),非西班牙裔(89.5%),男性(100%)。自我报告的创伤后应激障碍症状有显著改善(p<.001,d=.414),抑郁症(p<.001,d=.275),焦虑(p<.001,d=.276),失眠严重程度(p<.001,d=.351),和脑震荡后症状(p<.001,d=.389)以及自我报告的生活满意度(p<.001,d=.371),心理灵活性(p<.001,d=.313)和认知功能(p<.001,d=.265)从基线到一个月的随访。结论:数据表明,伊博加因和5-MeO-DMT辅助治疗有可能在心理健康功能方面提供快速而有力的变化,并具有长达6个月的持久治疗效果。有必要在受控环境中进行未来的研究。
Background: Research in psychedelic medicine has focused primarily on civilian populations. Further
study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in Mexico.Methods: Data were collected from an
ibogaine and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) clinical treatment program for SOFV with a history of trauma exposure. This clinical program collects prospective clinical program evaluation data, such as background characteristics, symptom severity, functioning (e.g., satisfaction with life, posttraumatic stress disorder symptoms, depression symptoms, anxiety symptoms, sleep disturbance, psychological flexibility, disability in functioning, cognitive functioning, neurobehavioral symptoms, anger, suicidal ideation), and substance persisting/enduring effects through online surveys at four timepoints (baseline/pre-treatment, one-, three-, and six-months after treatment).Results: The majority of the sample (n = 86; Mean Age = 42.88, SD = 7.88) were Caucasian (87.2%), non-Hispanic (89.5%), and males (100%). There were significant and large improvements in self-reported PTSD symptoms (p < .001, d = .414), depression (p < .001, d = .275), anxiety (p < .001, d = .276), insomnia severity (p < .001, d = .351), and post-concussive symptoms (p < .001, d = .389) as well as self-reported satisfaction with life (p < .001, d = .371), psychological flexibility (p < .001, d = .313) and cognitive functioning (p < .001, d = .265) from baseline to one-month follow-up.Conclusions: Data suggest combined
ibogaine and 5-MeO-DMT assisted therapy has potential to provide rapid and robust changes in mental health functioning with a signal of durable therapeutic effects up to 6-months. Future research in controlled settings is warranted.